Featured Research

from universities, journals, and other organizations

Drug Effective In Treatment Of Heavy Psoriasis Patients

Date:
August 4, 2007
Source:
Mount Sinai Medical Center
Summary:
A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis, had an acceptable safety and efficacy profile in the treatment of psoriasis in heavy patients, researchers recently announced.

A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis, had an acceptable safety and efficacy profile in the treatment of psoriasis in heavy patients, researchers at Mount Sinai School of Medicine recently announced.

Efalizumab showed similar safety and efficacy for non-heavy patients (those weighing under 200 lbs) and the more difficult-to-treat subpopulation of heavy patients (those weighing over 200 lbs). Additionally, treatment response was maintained for up to 36 months in both groups. The results were presented at the annual summer meeting of the American Academy of Dermatology in New York City.

“Overweight and obese psoriasis patients have a higher unmet need than typical psoriasis patients and present unique treatment challenges,” said Dr. Mark Lebwohl, Professor and Chairman, Department of Dermatology at Mount Sinai School of Medicine. “This patient subpopulation may have larger lesions and skin folds that limit the use of topical agents and phototherapy, as well as comorbidities such as cardiovascular and metabolic diseases that restrict the use of some systemic agents. Our study shows that Efalizumab, because of its weight-based dosing and long-term safety profile, may be an excellent choice of therapy in heavy psoriasis patients.”

About the Study

A meta-analysis of four randomized Phase III placebo-controlled trials was performed to evaluate the safety and efficacy of subcutaneous Efalizumab in patients with chronic moderate-to-severe plaque psoriasis with respect to patient weight. The Psoriasis Area and Severity Index (PASI) score was used to characterize efficacy, and adverse events were examined for safety.

The median patient weight was 91kg (200 lbs.), and a total of 3,877 patients were separated into two groups above and below 91kg: heavy (n=1980) and non-heavy (n=1897). At 12 weeks, efficacy was similar for the two groups with 28 percent of non-heavy patients and 25 percent of patients achieving PASI-75. At 24 weeks, efficacy was similar for the two groups with 42 percent of non-heavy patients and 43 percent of heavy patients achieving PASI-75. The incidence of adverse events and rate of infection was similar in both patient groups. The most common adverse events observed were a symptom complex that included headache, chills, fever, nausea, and myalgia within 48 hours following the first 2 injections.

About Psoriasis and Obesity

Psoriasis occurs when new skin cells grow abnormally, resulting in thick, red, and scaly, inflamed patches. Plaque psoriasis, the most common form of the disease, affects millions of Americans and is characterized by inflamed patches of skin ("lesions") topped with silvery white scales.

Patients with psoriasis are twice as likely to be overweight compared to the general population. They often gain weight because the disease limits their physical activity, or erodes their self-esteem and causes depression, leading the patient to eat excessively. Obesity is also associated with more severe psoriasis. Certain co-morbidities associated with heavy individuals such as hypertension, diabetes, or high cholesterol may influence a dermatologist’s choice of therapy for this subpopulation.

About Efalizumab

Efalizumab, marketed by Genentech as Raptivaฎ, is a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. In October 2003, Raptiva received U.S. Food and Drug Administration approval for the treatment of chronic moderate-to-severe plaque psoriasis in adults 18 years or older who are candidates for systemic therapy or phototherapy. Raptiva can be self-administered by patients as a single dose, once-weekly, subcutaneous injection after proper training by a healthcare professional.

The most serious side effects experienced by patients in trials with RAPTIVAฎ (efalizumab) were low platelet counts (thrombocytopenia), low blood counts (anemia), new or worsening psoriasis, and new or worsening arthritis. Because RAPTIVA is an immunosuppressive agent, it has the potential to increase the risk of infection and cancer. The most common side effects of RAPTIVA include headache, chills, fever, nausea, and muscle aches.


Story Source:

The above story is based on materials provided by Mount Sinai Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Mount Sinai Medical Center. "Drug Effective In Treatment Of Heavy Psoriasis Patients." ScienceDaily. ScienceDaily, 4 August 2007. <www.sciencedaily.com/releases/2007/08/070803145135.htm>.
Mount Sinai Medical Center. (2007, August 4). Drug Effective In Treatment Of Heavy Psoriasis Patients. ScienceDaily. Retrieved July 27, 2014 from www.sciencedaily.com/releases/2007/08/070803145135.htm
Mount Sinai Medical Center. "Drug Effective In Treatment Of Heavy Psoriasis Patients." ScienceDaily. www.sciencedaily.com/releases/2007/08/070803145135.htm (accessed July 27, 2014).

Share This




More Health & Medicine News

Sunday, July 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) — A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) — Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com
What's To Blame For Worst Ebola Outbreak In History?

What's To Blame For Worst Ebola Outbreak In History?

Newsy (July 27, 2014) — A U.S. doctor has tested positive for the deadly Ebola virus, as the worst-ever outbreak continues to grow. Video provided by Newsy
Powered by NewsLook.com
Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) — A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins